Biotech Values

[jbog]

Lilly and Novo commented on the system.

Fighting words: Lilly and Novo swat back at the Biden/Sanders call for lower GLP-1 prices

"Comparing list prices in the United States to other countries ignores patient affordability programs and hundreds of billions of dollars in discounts and fees paid to PBMs by pharmaceutical companies that should lower the costs of medicines for Americans, but unfortunately this system can drive prices higher," Lilly said.

https://finance.yahoo.com/news/fighting-words-lilly-and-novo-swat-back-at-the-bidensanders-call-for-lower-glp-1-prices-195341167.html